Last reviewed · How we verify

treosulfan + cytarabine — Competitive Intelligence Brief

treosulfan + cytarabine (treosulfan + cytarabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent + nucleoside analog combination. Area: Oncology.

phase 3 Alkylating agent + nucleoside analog combination Oncology Small molecule Live · refreshed every 30 min

Target snapshot

treosulfan + cytarabine (treosulfan + cytarabine) — University of Wuerzburg. Treosulfan and cytarabine work together as a chemotherapy combination that damages DNA in cancer cells, with treosulfan acting as an alkylating agent and cytarabine as a nucleoside analog.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
treosulfan + cytarabine TARGET treosulfan + cytarabine University of Wuerzburg phase 3 Alkylating agent + nucleoside analog combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent + nucleoside analog combination class)

  1. University of Wuerzburg · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). treosulfan + cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/treosulfan-cytarabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: